HCAT · Health Catalyst, Inc.
Market Cap
$128.69M
Shares
75.26M
Volume · Oct 20
81.01K
Avg daily vol (3M)
620.58K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.71
Open$1.72
Day$1.68–1.75
52W close$1.00–3.46
Avg vol 30d470K
Short int2.2M · 2.9% float · 5.2d
Short vol56%
Last earningsAug 6, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Oct 27, 2026
Est · unconfirmed
· in 1 wks
filed Aug 6, 2026
call held May 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$292.25M
Trailing 12 months
Net income (TTM)
−$264.82M
Trailing 12 months
Revenue growth YoY
-12.7%
Year over year
Operating margin
-84.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$50.04M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+6.2%
Year over year · more shares
Price change (1Y)
-43.9%
Trailing year
Short interest
2.9%
Latest settlement · 5.2 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Neutral
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
Death cross
Price vs 200-day avg
−2%
below
Price vs 50-day avg
−1%
below
RSI (14)
45
neutral
MACD trend
Negative
52-week position
29%
mid-range
Momentum
relative strength
1-month return
−6%
trailing
6-month return
+28%
trailing
YTD return
−28%
this year
Relative strength
+20%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Death cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
14 of 128 funds reported for Sep 30 · net -15.0K sh shares · +1 new
Insider flow
Accumulating
Net +$105.4K over 90 days · 0% sells
Short interest
Rising
2.94% of float · ▲ +9.1% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
128 holders — near 3-yr low, contrarian setup
Squeeze score
54
elevated · 0–100
Fundamentals
Revenue growth
+1%
Y/Y
EPS growth
−122%
Y/Y
Free cash flow
$-237.0K
Buyback
$24.8M
remaining
Balance sheet
$102.4M
net debt
Quant / Vol
risk profile
Volatility
90%
annualized · 1-yr
Max drawdown
−71%
past year
ATR
5.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed May 11, 2026
Adjusted EBITDA
· full year 2026
Non-GAAP
$30M – $33M
Total revenue
· full year 2026
$260M – $265M
prior FY $311.14M
midpoint −15.6% Y/Y
Prior guidance
period ended
· from the Earnings Call filed May 11, 2026
Total revenue
· Q2 2026
$68M – $70M
Guided vs delivered
· last 8 settled
Total revenue
Q2 2026
guided $68M – $70M
$70.49M
Beat +2.2%
Total revenue
first quarter of 2026
guided $68M – $70M
$70.76M
Beat +2.5%
Total revenue
full year 2025
guided $310M
$311.14M
Beat +0.4%
Total revenue
fourth quarter of 2025
guided $73.5M
$74.68M
Beat +1.6%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
Death cross
Bearish
Price vs 200-day avg
−2%
Neutral
Price vs 50-day avg
−1%
Neutral
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
29%
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
Death cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
14 of 128 funds reported for Sep 30 · net -15.0K sh shares · +1 new
Insider flow
Accumulating
Net +$105.4K over 90 days · 0% sells
Short interest
Rising
2.94% of float · ▲ +9.1% MoM · 5.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
128 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $2 · 29%
Range high $3
vs 200-day avg -2%
vs 50-day avg -1%
50-day below 200-day death cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Cost of Revenue non-GAAP | 34.65M | Three Months Ended June 30, 2026 | — |
| Adjusted EBITDA non-GAAP | $9.92M | Three Months Ended June 30, 2026 | +6.2% |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Net loss -40.54M
+3.74M Interest and other (income) expense, net
+315K Income tax provision
+10.98M Depreciation and amortization
+2.71M Stock-based compensation
+1.96M Acquisition-related costs, net
+3.71M Restructuring costs
+27.05M Goodwill impairment
= Adjusted EBITDA 9.92M
|
|||
| Adjusted Gross Margin non-GAAP | 51% | the three months ended June 30, 2026 filing | +2.0% |
|
|
|||
| Adjusted Gross Profit non-GAAP | $35.84M | Three Months Ended June 30, 2026 | -10.3% |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Gross profit 27.86M
+3.73M Amortization of intangible assets, cost of revenue
+3.27M Depreciation of property and equipment, cost of revenue
+417K Stock-based compensation
+560K Restructuring costs
= Adjusted Gross Profit 35.84M
|
|||
| Adjusted Net Income non-GAAP | 2.7M | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss -40.54M
+2.71M Stock-based compensation
+7.3M Amortization of acquired intangibles
+3.71M Restructuring costs
+1.96M Acquisition-related costs, net
+27.05M Goodwill impairment
+521K Non-cash interest expense related to debt facilities
= Adjusted Net Income 2.7M
|
|||
| Adjusted Net Income per share, basic and diluted non-GAAP | $0.04 | Three Months Ended June 30, 2026 | — |
| Adjusted Operating Expenses non-GAAP | 25.92M | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Total operating expenses 71.34M
-10.98M Depreciation and amortization
-2.29M Stock-based compensation
-1.96M Acquisition-related costs, net
-27.05M Goodwill impairment
-3.15M Restructuring costs
= Adjusted Operating Expenses 25.92M
|
|||
| Adjusted Operating Expenses as a % of revenue non-GAAP | 37% | Three Months Ended June 30, 2026 | — |
| Vitalware Adjusted EBITDA non-GAAP | 11.36M | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HCAT
this stock
Health Catalyst, Inc.
|
$128.69M | -28.5% | +1.5% | — | 2.9% |
|
VEEV
Veeva Systems Inc
|
$51.57B | +41.9% | +28.1% | 52.1 | 3.0% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$12.77B | -26.4% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$12.10B | +63.7% | +28.2% | 37.1 | 6.1% |
|
TEM
Tempus AI, Inc.
|
$11.61B | +9.0% | +83.4% | — | 13.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HCAT | -2.3% | -5.5% | +27.6% | -1.2% | -28.5% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -0.8% | -4.6% | +19.9% | -1.7% | -40.9% |
Capital returns
Buyback program
· as of Jun 30, 2026
Authorized
$40.00M
Spent (derived)
$15.20M
Remaining
$24.80M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.